Drugs / TCR-T cells
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07342738 | Feb 2026 → Feb 2028 expected | cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05648994 | Dec 2022 → Feb 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06904859 | Jan → Dec 2019 | acute myeloid leukemia | Shenzhen University General Hospital | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03778814 | Dec 2018 → Dec 2029 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT04677088 | Mar 2018 → Feb 2020 | hepatocellular carcinoma | Xiaoshun He | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07614048 | — | colorectal cancer, pancreatic ductal adenocarcinoma | Providence Health & Services | Temporarily not available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-11-09 | Lion TCR Pte. Ltd. | Results Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022 liontcr.com ↗
The data conclusively demonstrated the differential liver function, viral and immune alterations in patient with and without clinical response, implicating the importance of secondary immune response activation via the cancer-immunity cycle for durable anti-tumor effects of LioCyx-M. |
| 2016-05-26 | Lion TCR Pte. Ltd. | Results Dr. Antonio Bertoletti presents Lion TCR T-cell therapy at the International Society for Cellular Therapy Conference 2016 liontcr.com ↗
He further presented our latest clinical results in treating liver transplant patients with chemotherapy-resistant HCC metastases. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-09 | Lion TCR Pte. Ltd. | Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022 liontcr.com ↗ |
| 2016-05-26 | Lion TCR Pte. Ltd. | Dr. Antonio Bertoletti presents Lion TCR T-cell therapy at the International Society for Cellular Therapy Conference 2016 liontcr.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T cells | “Cells will be administered at a dose of between 1x109 to 1x1010 TCR-T cells.” NCT07614048 ↗ |
| Action | Deplete | “Test the quality and killing activity of the TCR-T cells in vitro” NCT03778814 ↗ |
| Modality | Cell therapy | “TCR-T cell immunotherapy” NCT03778814 ↗ |
| Route | Intravenous | “via vein” NCT03778814 ↗ |
| Target | KRAS | “TCR-T cells targeted for KRAS mutation” NCT07342738 ↗ |